Neurocrine Biosciences (NBIX) Prepaid Assets (2010 - 2026)

Neurocrine Biosciences has reported Prepaid Assets for 17 years, with the latest figure at $224.8 million in Q1 2026.

• For the quarter ending Q1 2026, Prepaid Assets rose 88.43% year-over-year to $224.8 million; the trailing twelve-month figure through Mar 2026 stood at $224.8 million (up 88.43% YoY), and the FY2025 full-year result was $115.8 million, up 82.08% from the prior year.
• Prepaid Assets for Q1 2026 stood at $224.8 million, up from $115.8 million in the prior quarter.
• The five-year high for Prepaid Assets was $224.8 million in Q1 2026, with the low at $60.8 million in Q1 2022.
• Historically, Prepaid Assets has averaged $109.1 million across 5 years, with a median of $108.2 million in 2023.
• Annual changes were most pronounced in 2024 — Prepaid Assets tumbled 34.97% — and 2026, when it surged 88.43%.
• Neurocrine Biosciences' Prepaid Assets stood at $79.1 million in 2022, then rose by 23.64% to $97.8 million in 2023, then plunged by 34.97% to $63.6 million in 2024, then surged by 82.08% to $115.8 million in 2025, then soared by 94.13% to $224.8 million in 2026.
• The last three Prepaid Assets figures came in at $224.8 million (Q1 2026), $115.8 million (Q4 2025), and $178.1 million (Q3 2025), per Business Quant data.